Loading...
XSHG603707
Market cap2.99bUSD
Dec 24, Last price  
13.48CNY
1D
1.28%
1Q
4.50%
IPO
53.53%
Name

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603707 chart
P/E
—
P/S
5.54
EPS
—
Div Yield, %
1.14%
Shrs. gr., 5y
5.36%
Rev. gr., 5y
18.25%
Revenues
3.93b
+5.89%
499,817,300416,121,068468,728,013581,913,0371,112,726,0031,700,330,6672,469,669,3052,914,880,9303,686,692,9513,712,720,4553,931,387,279
Net income
-189m
L
70,316,20050,490,00587,553,459257,239,597314,222,399424,549,136604,961,604806,122,1851,059,293,3311,090,833,203-189,445,790
CFO
1.62b
+171.93%
193,913,400178,740,925137,280,5650062,368,49300683,631,820595,445,6731,619,167,843
Dividend
Jul 08, 20240.1 CNY/sh
Earnings
May 16, 2025

Profile

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.
URL
https://www.nkf-pharma.com/
IPO date
Jul 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,931,387
5.89%
3,712,720
0.71%
3,686,693
26.48%
Cost of revenue
2,865,976
2,546,496
2,341,899
Unusual Expense (Income)
NOPBT
1,065,412
1,166,225
1,344,794
NOPBT Margin
27.10%
31.41%
36.48%
Operating Taxes
(105,312)
98,850
139,838
Tax Rate
8.48%
10.40%
NOPAT
1,170,723
1,067,375
1,204,956
Net income
(189,446)
-117.37%
1,090,833
2.98%
1,059,293
31.41%
Dividends
(248,469)
(186,586)
(140,406)
Dividend yield
1.05%
0.64%
0.21%
Proceeds from repurchase of equity
(5,722)
BB yield
0.02%
Debt
Debt current
1,566,802
1,957,288
1,570,663
Long-term debt
532,663
1,023,075
474,581
Deferred revenue
84,987
65,506
Other long-term liabilities
82,738
6,170
6,170
Net debt
135,192
1,530,249
1,126,892
Cash flow
Cash from operating activities
1,619,168
595,446
683,632
CAPEX
(419,068)
Cash from investing activities
(1,176,382)
170,143
Cash from financing activities
51,200
FCF
3,399,723
(144,004)
349,793
Balance
Cash
1,891,797
1,389,812
918,352
Long term investments
72,478
60,303
Excess cash
1,767,705
1,264,479
734,017
Stockholders' equity
4,748,396
5,597,469
4,440,523
Invested Capital
6,199,766
7,950,988
6,753,854
ROIC
16.55%
14.52%
19.15%
ROCE
13.31%
12.60%
17.96%
EV
Common stock shares outstanding
1,578,715
1,614,629
1,582,852
Price
15.00
-16.85%
18.04
-57.05%
42.00
55.44%
Market cap
23,680,724
-18.70%
29,127,902
-56.19%
66,479,794
56.09%
EV
23,812,446
30,654,679
67,631,522
EBITDA
1,219,471
1,305,757
1,438,015
EV/EBITDA
19.53
23.48
47.03
Interest
81,045
57,847
92,215
Interest/NOPBT
7.61%
4.96%
6.86%